NasdaqGS:CERTHealthcare Services
Will Certara’s Softer Bookings and New Strategy Redefine Its Competitive Edge (CERT)?
In its fourth-quarter 2025 investor letter, Meridian Growth Fund reported that Certara, Inc. underperformed after service bookings came in weaker than expected, prompting management to slightly lower guidance.
The fund also pointed to Certara’s ongoing transformation under a new CEO, including a more commercially focused approach and potential sale of a non-core business, even as its biosimulation tools supported a majority of recent FDA drug approvals.
Next, we’ll examine how softer...